Area of Interest

We are addressing myopia comprehensively by conducting research into the experiences and needs of patients and their families across all stages of the disease, and by leveraging these insights in our approach. To protect children from the risk of vision problems associated with myopia, we are working to promote a proper understanding of the disease, informed by the expertise of medical and research professionals. Our initiatives include developing a low concentration atropine formulation along with proper disease awareness activities, advancing　a next-generation drug with better efficacy and safety, and creating greater value for patients through collaboration with external partners during drug discovery. 

Ptosis is a unilateral or bilateral drooping of the upper eyelid that usually occurs from a partial or complete dysfunction of the muscles that elevate the upper eyelid. It can lead to decreased visual fields and lower quality of life (QOL) for patients. Tens of millions of adults are suffering from ptosis globally^*2,3. ​The oxymetazoline ophthalmic solution we are developing as a treatment for blepharoptosis was approved in Japan in December 2025, and Phase 3 clinical trials are currently underway in Europe and China. Oxymetazoline has been reported to act as an agonist for the α₁- and α₂-adrenergic receptors. By acting on α receptors in Müller’s muscle, which contributes to eyelid elevation, the product induces muscle contraction and lifts the upper eyelid.